173 related articles for article (PubMed ID: 35150959)
21. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
22. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
23. Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway.
Luo D; Zeng X; Zhang S; Li D; Cheng Z; Wang Y; Long J; Hu Z; Long S; Zhou J; Zhang S; Zeng Z
J Cell Mol Med; 2023 Feb; 27(3):456-469. PubMed ID: 36651490
[TBL] [Abstract][Full Text] [Related]
24. VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway.
Xu X; Liu M; Yang Y; Wei C; Zhang X; Song H; Wang Y; Duan X
Oncol Rep; 2021 Mar; 45(3):975-986. PubMed ID: 33650675
[TBL] [Abstract][Full Text] [Related]
25. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
Guo Y; Fan Y; Pei X
Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
[TBL] [Abstract][Full Text] [Related]
26. CUL1 Knockdown Attenuates the Adhesion, Invasion, and Migration of Triple-Negative Breast Cancer Cells via Inhibition of Epithelial-Mesenchymal Transition.
Ren ZQ; Yan WJ; Zhang XZ; Zhang PB; Zhang C; Chen SK
Pathol Oncol Res; 2020 Apr; 26(2):1153-1163. PubMed ID: 31175550
[TBL] [Abstract][Full Text] [Related]
27. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
28. Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway.
Hseu YC; Lin YC; Rajendran P; Thigarajan V; Mathew DC; Lin KY; Way TD; Liao JW; Yang HL
Food Chem Toxicol; 2019 Feb; 124():219-230. PubMed ID: 30529123
[TBL] [Abstract][Full Text] [Related]
29. MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.
Wang J; Li M; Han X; Wang H; Wang X; Ma G; Xia T; Wang S
Cell Death Dis; 2020 Jul; 11(7):500. PubMed ID: 32620748
[TBL] [Abstract][Full Text] [Related]
30. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
[TBL] [Abstract][Full Text] [Related]
31. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
32. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
33. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
[TBL] [Abstract][Full Text] [Related]
35. TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.
Shi D; Zhao S; Jiang W; Zhang C; Liang T; Hou G
Cell Death Dis; 2019 Dec; 10(12):954. PubMed ID: 31852883
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
[TBL] [Abstract][Full Text] [Related]
37. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
38. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
39. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
[TBL] [Abstract][Full Text] [Related]
40. Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6.
Xue W; Hao J; Zhang Q; Jin R; Luo Z; Yang X; Liu Y; Lu Q; Ouyang Y; Guo H
J Pharmacol Exp Ther; 2023 Feb; 384(2):254-264. PubMed ID: 36456194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
